Fenofibrate as a COVID-19 modifying drug: laboratory success versus real-world reality

Ähnliche Einträge

• Does real world use of liraglutide match its use in the LEADER cardiovascular outcome trial? study protocol
  von: Hinton, W, et al.
  Veröffentlicht: (2019)
• Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
  von: Hinton, W, et al.
  Veröffentlicht: (2019)
• Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
  von: Hinton, W, et al.
  Veröffentlicht: (2021)
• Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
  von: Hinton, W, et al.
  Veröffentlicht: (2020)
• Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
  von: McGovern, A, et al.
  Veröffentlicht: (2017)